First-Line Treatment Options for Patients with HER-2–Negative Metastatic Breast Cancer: The Impact of Modern Adjuvant Chemotherapy-Reference-Cited by-同舟云学术

First-Line Treatment Options for Patients with HER-2–Negative Metastatic Breast Cancer: The Impact of Modern Adjuvant Chemotherapy

Published:2007-07-01 Issue:7 Volume:12 Page:785-797
ISSN:1083-7159
Container-title:The Oncologist
language:en
Short-container-title:

Author:

Verma Sunil¹,Clemons Mark²

Affiliation:

1. a Division of Medical Oncology, Sunnybrook and Women's College Health Sciences Centre, Toronto, Canada

2. b Princess Margaret Hospital, Toronto, Canada

Abstract

Learning Objectives After completing this course, the reader will be able to: Describe how changes in adjuvant treatment are having a major influence on treatment options in the first-line setting for metastatic breast cancer.Select the most appropriate first-line treatment for a patient with metastatic breast cancer based on previous adjuvant therapy.Discuss how as treatment options become more complex, there may no longer be a single “gold standard” therapy, and a variety of factors must be considered when selecting therapy. CME Access and take the CME test online and receive 1 AMA PRA Category 1 Credit™ at CME.TheOncologist.com

Funder

Medi-Kelsey Limited

Publisher

Oxford University Press (OUP)

Subject

Cancer Research,Oncology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1634/theoncologist.12-7-785

Reference76 articles.

1. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: An overview of the randomised trials;Early Breast Cancer Trialists' Collaborative Group (EBCTCG);Lancet,2005

2. Paclitaxel after doxorubicin plus cyclophosphamide as adjuvant chemotherapy for node-positive breast cancer: Results from NSABP B-28;Mamounas;J Clin Oncol,2005

3. Improved outcomes from adding sequential paclitaxel but not from escalating doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer;Henderson;J Clin Oncol,2003

4. Five years analysis of the PACS 01 trial: 6 cycles of FEC100 vs 3 cycles of FEC100 followed by 3 cycles of docetaxel (D) for the adjuvant treatment of node positive breast cancer;Roché;Breast Cancer Res Treat,2004

Cited by 24 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cellular Pathogenesis of Chemotherapy-Induced Peripheral Neuropathy: Insights From Drosophila and Human-Engineered Skin Models;Frontiers in Pain Research;2022-07-08

2. Clinical usefulness of eribulin as first- or second-line chemotherapy for recurrent HER2-negative breast cancer: a randomized phase II study (JBCRG-19);International Journal of Clinical Oncology;2021-04-23

3. Edible Tuber Amorphophallus paeoniifolius (Dennst.) Extract Induces Apoptosis and Suppresses Migration of Breast Cancer Cells;Nutrition and Cancer;2020-10-09

4. Disruption of the Rbm38-eIF4E Complex with a Synthetic Peptide Pep8 Increases p53 Expression;Cancer Research;2018-12-27

5. Eribulin in advanced breast cancer: safety, efficacy and new perspectives;Future Oncology;2017-12